Heart Test Operating Income Over Time
| HSCS Stock | USD 3.83 0.41 11.99% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Heart Test Performance and Heart Test Correlation. Heart |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heart Test. If investors know Heart will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heart Test listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 5.35 | Revenue Per Share 0.036 | Quarterly Revenue Growth 6.538 | Return On Assets (0.82) | Return On Equity (2.69) |
The market value of Heart Test Laboratories is measured differently than its book value, which is the value of Heart that is recorded on the company's balance sheet. Investors also form their own opinion of Heart Test's value that differs from its market value or its book value, called intrinsic value, which is Heart Test's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heart Test's market value can be influenced by many factors that don't directly affect Heart Test's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heart Test's value and its price as these two are different measures arrived at by different means. Investors typically determine if Heart Test is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heart Test's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Heart Test Laboratories and related stocks such as Tivic Health Systems, Talis Biomedical Corp, and Bluejay Diagnostics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TIVC | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.2 M) | (5.6 M) | (10.1 M) | (8.2 M) | (8.7 M) |
| BJDX | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.2 M) | (3.2 M) | (9.3 M) | (10.3 M) | (9.8 M) |
| NUWE | (1.2 M) | (16.6 M) | (14.9 M) | (22.9 M) | (25.8 M) | (26 M) | (15.7 M) | (14.8 M) | (17 M) | (18.1 M) | (17 M) | (19.5 M) | (17.2 M) | (17.6 M) | (18.5 M) |
| NURO | (9.1 M) | (10 M) | (10 M) | (7.4 M) | (8.8 M) | (13.3 M) | (15.2 M) | (13.1 M) | (12.3 M) | (11.5 M) | (2.1 M) | (2.3 M) | (4.7 M) | (7.2 M) | (7.5 M) |
| RSLS | (1.9 M) | (25.3 M) | (22.5 M) | (24.7 M) | (25.6 M) | (27.9 M) | (22.8 M) | (31.4 M) | (38.5 M) | (15.9 M) | (12.5 M) | (27.7 M) | (27.1 M) | (14.6 M) | (15.4 M) |
| IINN | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (6.3 M) | (13.4 M) | (14.8 M) | (12.1 M) | (12.7 M) |
| BBLG | (13.3 K) | (3 K) | (436) | (672) | (3 M) | (12 M) | (17.8 M) | (2.6 M) | (2.8 M) | (2.4 M) | (825 K) | (1.1 M) | (3.7 M) | (9.4 M) | (9 M) |
| TNON | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (533.4 K) | (536.3 K) | (6.5 M) | (18.7 M) | (15.7 M) | (14.9 M) |
| BVS | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | 20 K | (16.6 M) | 25.5 M | 25.5 M | 25.5 M | 31.2 M | 21.2 M | 17.7 M | (35.7 M) | (81.7 M) | (77.6 M) |
Heart Test Laboratories and related stocks such as Tivic Health Systems, Talis Biomedical Corp, and Bluejay Diagnostics Operating Income description
Operating Income is the amount of profit realized from Heart Test Laboratories operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Heart Test Laboratories is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Heart Test Laboratories | HSCS |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.83
Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.